- Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseasesLast month, Ascidian Therapeutics presented the first data suggesting a new way to fix broken genes may be safe in people. Now Eli Lilly has struck a deal with the startup. Ascidian’s ...Endpoints · 1mo ago↗ source
- Lilly, Ascidian link up in RNA exon editing pactWorth as much as $1.9 billion, the deal directs Ascidian to help Lilly find potential drugs for genetically driven kidney diseases.BioPharma Dive · 1mo ago↗ source
- Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trialGedatolisib could “establish a new standard of care” for PIK3CA-mutated breast cancer, an investigator said, but the results nonetheless appeared to disappoint investors.